A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective studySheri L. Spunt, Douglas S. Hawkins, Jing Tian et al.|The Lancet Oncology|2019Cited by 182
Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332.Sheri L. Spunt, Alberto S. Pappo, Lynn Million et al.|Journal of Clinical Oncology|2014Cited by 30